AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Aligos Therapeutics Reports Q2 EPS of $1.53, Misses Consensus
ByAinvest
Friday, Aug 8, 2025 7:39 am ET1min read
Aligos Therapeutics reported Q2 EPS of ($1.53) and revenue of $965,000, exceeding consensus estimates of ($2.54) and $433,330. The company's Phase 2 B-SUPREME study for ALG-000184 is underway, with regulatory approvals across several countries and dosing expected to commence soon. The Phase 1 data presented at the EASL meeting suggests that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure.
Aligos Therapeutics, Inc. (ALGS) reported a Q2 2025 loss of $1.53 per share, surpassing the Zacks Consensus Estimate of a loss of $2.35 [1]. This compares to earnings of $0.75 per share a year ago. The company also reported revenues of $0.97 million for the quarter, missing the Zacks Consensus Estimate by 3.5% [1]. These figures are adjusted for non-recurring items.The company's Phase 2 B-SUPREME study for ALG-000184 is progressing, with regulatory approvals across several countries and dosing expected to commence soon. Phase 1 data presented at the EASL meeting suggested that ALG-000184 has the potential to replace standard of care treatment for chronic HBV infection and may become the backbone of treatments aimed at a functional cure [2].
Over the last four quarters, Aligos Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once. The company's shares have lost about 80.2% since the beginning of the year versus the S&P 500's gain of 7.1% [1].
The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock. The Medical - Biomedical and Genetics industry is currently in the bottom 42% of the 250 plus Zacks industries [1].
References:
[1] https://www.nasdaq.com/articles/aligos-therapeutics-inc-algs-reports-q2-loss-misses-revenue-estimates
[2] https://www.biospace.com/press-releases/alkeus-pharmaceuticals-announces-presentation-of-positive-interim-tease-3-study-data-in-early-stage-stargardt-disease-patients-treated-with-oral-gildeuretinol
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet